WETS
IOVA icon

Wealth Enhancement Trust Services’s Iovance Biotherapeutics IOVA Stock Holding History

Wealth Enhancement Trust Services’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.1K Buy
9,404
+404
+4% +$1.53K ﹤0.01% 531
2026
Q1 		$31.6K Buy
9,000
+5,000
+125% +$16K ﹤0.01% 503
2025
Q4 		$10.9K Buy
+4,000
New +$9.25K ﹤0.01% 556

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
OIC
Orion Investment Company St. Louis, Missouri $343M AUM 52.59% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Wealth Enhancement Trust Services's IOVA Position: Q2 2026 in Review

Wealth Enhancement Trust Services increased its Iovance Biotherapeutics (IOVA) stake by 4.5% in Q2 2026, buying an estimated $1.53K and bringing the position to 9,404 shares worth $39.1K. The position accounts for ﹤0.01% of the portfolio, ranked #531.

Wealth Enhancement Trust Services first reported a position in IOVA in Q4 2025 and has held it in 3 quarters since. 191 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Wealth Enhancement Trust Services held 9,404 shares of Iovance Biotherapeutics worth $39.1K as of Q2 2026.
  • Wealth Enhancement Trust Services bought 404 Iovance Biotherapeutics shares in Q2 2026, an estimated $1.53K.
  • Iovance Biotherapeutics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #531 holding.
  • Wealth Enhancement Trust Services first reported a position in Iovance Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 191 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.